Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

NCT00237159 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00237159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00237159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2002
Completion date
Not reported
Enrollment
284 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer patients with bone metastasis